HN21C1077

Preclinical development of HM97662, an epigenetic protein EZH1/2 dual inhibitor, as a treatment for various cancers

Hanmi Pharmaceutical, Co., Ltd.

Global · R&D 선도
한미약품(주)

ONCOLOGY | **Non-Clinical**

Product Type	Chemical Product (Small Molecule)
Indication	Hematplogical malignancies (e.g. T cell lymphoma) Solid tumors (e.g. ovarian & bladder cancers)
Target	Enhancer of Zeste Homolog 1 and 2 (EZH1 and EZH2)
MoA(Mechanism of Action)	Dual inhibition of EZH1 and EZH2, the enzymatic core subunits of PRC2 complex that catalyze methylation of H3K27, to regulate the transcription of different genes including tumor suppressor
Competitiveness	• Potent activity against EZH1-elevated cancer cells resistant to Tazemetostat • Enhancement of response to ICBs in KRAS mutated cells with LKB1 loss through STING induction • Effective antitumor activity in xenograft models of various blood and solid cancer cells harboring EZH2 or PRC2 complex-regulating proteins
Development Stage	IND submitted (June 2022: MFDS, Korea)
Route of Administration	Oral Administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund